These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1026530)

  • 21. [Effects of intravenous disopyramide on induction and termination of paroxysmal supraventricular tachycardia via an accessory pathway].
    Komatsu C; Ishinaga T; Tateishi O; Tokuhisa Y; Hara M; Sanada T; Kanae K; Satoh Y; Yoshimura S
    Kokyu To Junkan; 1984 Apr; 32(4):409-14. PubMed ID: 6463419
    [No Abstract]   [Full Text] [Related]  

  • 22. Anti-arrhythmic and haemodynamic effects of intravenous and oral disopyramide in patients with ventricular arrhythmia.
    Hulting J; Rosenhamer G
    J Int Med Res; 1976; 4(1 Suppl):90-5. PubMed ID: 1026537
    [No Abstract]   [Full Text] [Related]  

  • 23. Clinical studies of Norpace (Part V).
    Cook WR
    Angiology; 1975 Jan; 26(1 Pt 2):140-1. PubMed ID: 1115401
    [No Abstract]   [Full Text] [Related]  

  • 24. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
    Aitio ML; Allonen H; Kanto J; Mäntylä R
    Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Bioavailability of procainamide and disopyramide with and without concomitant administration of an antacid: aluminium phosphate (author's transl)].
    Albin H; Vinçon G; Bertolaso D; Dangoumau J
    Therapie; 1981; 36(5):541-6. PubMed ID: 7323992
    [No Abstract]   [Full Text] [Related]  

  • 26. Concentration-response relationships of disopyramide in patients with ventricular tachycardia.
    Duff HJ; Mitchell LB; Nath CF; Manyari DE; Baynton R; Wyse DG
    Clin Pharmacol Ther; 1989 May; 45(5):542-7. PubMed ID: 2721110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disopyramide kinetics in patients with acute myocardial infarction.
    Ilett KF; Madsen BW; Woods JD
    Clin Pharmacol Ther; 1979 Jul; 26(1):1-7. PubMed ID: 445953
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical pharmacology of disopyramide].
    Rewerski W; Dorociak A; Walczak F; Dobiasz A
    Pol Tyg Lek; 1980 Jul; 35(29):1109-12. PubMed ID: 7001399
    [No Abstract]   [Full Text] [Related]  

  • 29. Respiratory difficulty after use of disopyramide.
    Porterfield JG; Antman EM; Lown B
    N Engl J Med; 1980 Sep; 303(10):584. PubMed ID: 7402225
    [No Abstract]   [Full Text] [Related]  

  • 30. Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.
    Lien E; Bakke OM
    Br J Clin Pharmacol; 1983 Jul; 16(1):71-6. PubMed ID: 6882625
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.
    Cook CS; Karim A; Sollman P
    Drug Metab Dispos; 1982; 10(2):116-21. PubMed ID: 6124395
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pharmacodynamics and pharmacokinetics of disopyramide phosphate].
    Ol'binskaia LI; Tiukavkina NA; Kuz'mina MM; Beloborodov VL; Klimov AV
    Farmakol Toksikol; 1985; 48(4):73-8. PubMed ID: 3930285
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Use of intravenous disopyramide in the treatment of symptomatic refractory ventricular arrhythmia].
    Leone A
    Minerva Cardioangiol; 1984 Mar; 32(3):151-6. PubMed ID: 6728204
    [No Abstract]   [Full Text] [Related]  

  • 34. [Pharmacokinetic and metabolic study of disopyramide in oral and intravenous administration].
    De Graeve J; Kremers P; Gielen JE
    Therapie; 1977; 32(2):195-204. PubMed ID: 898127
    [No Abstract]   [Full Text] [Related]  

  • 35. [Induction and termination of ventricular tachycardia by programmed electrical stimulation of heart--a case in which the effect of disopyramide phosphate was confirmed by the stimulation study (author's transl)].
    Komatsu C; Ishinaga T; Motoyama M; Marutani K; Teruya H; Nakayama M; Kuno A; Sato Y; Yoshimura S
    Kokyu To Junkan; 1981 Feb; 29(2):209-15. PubMed ID: 6789431
    [No Abstract]   [Full Text] [Related]  

  • 36. [Evaluation of the efficacy of anti-arrhythmia agents in hyperkinetic ventricular arrhythmia].
    Bracchetti D; Mantovani B; Naccarella F; Lombardi G; Palmieri M
    Boll Soc Ital Cardiol; 1980; Suppl():117-23. PubMed ID: 7349604
    [No Abstract]   [Full Text] [Related]  

  • 37. Disopyramide in ventricular tachycardia.
    Hulting J; Rosenhamer G
    Acta Med Scand; 1976; 200(3):209-13. PubMed ID: 970227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness of propafenon and disopyramide in ventricular extrasystole. Comparative study].
    Kenedi P
    MMW Munch Med Wochenschr; 1982 Aug; 124(34):734-6. PubMed ID: 6182460
    [No Abstract]   [Full Text] [Related]  

  • 39. [Delayed-action disopyramide in the treatment of hyperkinetic ventricular arrhythmia. A randomized clinical comparative study vs immediate-action disopyramide].
    Romanò M; Spinelli A; Cazzani E; Muzio L
    Clin Ter; 1991 Jul; 138(1):13-9. PubMed ID: 1834395
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Disopyramide hemodialysis and kinetics in patients requiring long-term hemodialysis.
    Sevka MJ; Matthews SJ; Nightingale CH; Izard MW; Fieldman A; Chow MS
    Clin Pharmacol Ther; 1981 Mar; 29(3):322-6. PubMed ID: 7471602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.